Tirzepatide and Acute Pancreatitis: Pancreatology | March 2026

Introduction

With the rapid rise of obesity and type 2 diabetes, incretin-based therapies such as Tirzepatide have transformed metabolic care. These agents offer substantial benefits in weight reduction and glycemic control, approaching outcomes seen with bariatric surgery. However, as their use expands globally, safety concerns—particularly the potential risk of acute pancreatitis—have come under increasing scrutiny. Given that pancreatitis has multifactorial causes, understanding whether tirzepatide independently contributes to this risk, and whether this risk is dose-dependent, is clinically important.

Problem Statement

There is uncertainty regarding whether tirzepatide increases the risk of acute pancreatitis and whether this risk varies across commonly used doses (5 mg, 10 mg, 15 mg).

Summary

This large meta-analysis of 19 randomized trials including over 15,000 patients provides reassuring evidence that acute pancreatitis with tirzepatide is extremely rare (≈0.22%) and shows no dose–response relationship across therapeutic doses. Comparative analyses between 5 mg, 10 mg, and 15 mg doses demonstrated no statistically significant differences in pancreatitis risk, and results remained consistent across multiple sensitivity and advanced statistical models.

Importantly, patient-related factors such as age and sex did not significantly influence risk. However, limitations include short follow-up durations and industry-funded trials, highlighting the need for long-term real-world data.

Clinically, tirzepatide appears safe from a pancreatitis standpoint, but vigilance remains essential—especially in patients with traditional risk factors such as gallstones, alcohol use, or hypertriglyceridemia.